Perspectives on brain-targeting drug delivery systems.
Abstract
Due to the presence of the blood-brain barrier, there is limited drug access into the brain. In order to overcome this challenge, various strategies have been developed to enhance penetration of drugs into the brain. Of these, the most frequently used are pharmacological technologies or comparable methods being developed for brain-targeting drug delivery using receptor- or adsorptive- or transporter-mediated transcytosis and the nose-to-brain route. It goes without saying that exploration of Brain-targeting drug delivery systems has created another potential option for the treatment of central nervous system diseases. In addition to above methods, other technologies for brain-targeting drug delivery (e.g. chemical delivery systems, prodrugs, pharmacological disruption of the BBB and inhibition of drug efflux by P-glycoprotein) are also summaried in this review. Keywords: Blood-brain barrier, brain-targeting drug delivery systems, receptor-mediated transcytosis, adsorptive-mediated transcytosis, transporter-mediated transcytosis, nose-to-brain, chemical delivery systems, prodrugs, P-glycoprotein, Targeting drug delivery, colloidal drug, harmful blood-borne substances, small molecule drugs, endothelium cells
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Nanocarrier-based brain targeted delivery can be accomplished via receptor-mediated, transporter-mediated, and pharmacological disruption of the BBB.
“Nanocarrier based brain targeted delivery can be accomplished via receptor-mediated, transporter-mediated and pharmacological disruption of BBB.”
From Nanotechnology: A Promising Approach for Delivery of Neuroprotective Drugs (2020) · cites this paper as Guo et al., 2012
Cited by
Sorted by citations
Is there new hope for therapeutic matrix metalloproteinase inhibition?
Vandenbroucke, R. E., & Libert, C. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4390 · Cited by 840 · see citing works
Progress and perspectives on targeting nanoparticles for brain drug delivery
Gao, H. (2016) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2016.05.013 · Cited by 505 · see citing works
Nanotechnology: A Promising Approach for Delivery of Neuroprotective Drugs
Naqvi, S., Panghal, A., & Flora, S. J. S. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00494 · Cited by 305 · see citing works
Dendrimer-Based Drug Delivery Systems for Brain Targeting
Zhu, Y., Liu, C., & Pang, Z. (2019) · Biomolecules · doi:10.3390/biom9120790 · Cited by 220 · see citing works
“Receptors on the BBB generally involved in brain drug delivery via RMT include insulin receptor [97], transferrin receptor [102–104], nicotinic acetylcholine receptor [105], insulin-like growth factor receptor [102], diphtheria toxin receptor [102], neonatal Fc receptor [98], scavenger receptor [102], receptor of adva…”
BackgroundRecent progress of drug nanoformulations targeting to brain
Khan, A. R., Yang, X., Fu, M., & Zhai, G. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.10.004 · Cited by 212 · see citing works
Liposome delivery systems for the treatment of Alzheimer’s disease
Ross, C., Taylor, M., Fullwood, N., & Allsop, D. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s183117 · Cited by 198 · see citing works
Intrathecal delivery of protein therapeutics to the brain: a critical reassessment.
Calias, P., Banks, W., Begley, D., Scarpa, M., & Dickson, P. (2014) · Pharmacology and Therapeutics · doi:10.1016/j.pharmthera.2014.05.009 · Cited by 157 · see citing works
“…transporters, exosomes, liposomes, nanoparticles, chimeric peptides, prodrugs), while the second category consists of techniques that bypass the BBB altogether via direct delivery to the CNS (Smith et al., 2004; Alam et al., 2010; Tan et al., 2010; Guo et al., 2012; Vlieghe & Khrestchatisky, 2013).”
Target specific tight junction modulators
Brunner, J., Ragupathy, S., & Borchard, G. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.02.008 · Cited by 167 · see citing works
Targeted Delivery of Nano-Therapeutics for Major Disorders of the Central Nervous System
Gao, H., Pang, Z., & Jiang, X. (2013) · Pharmaceutical Research · doi:10.1007/s11095-013-1122-4 · Cited by 164 · see citing works
“In addition to receptors, transporters on the BBB can also be used for brain-targeted delivery, including amino acid transporters, hexose transporters and monocarboxylate transporters (6).”
BackgroundInfluentialSelf-citationGao, H., Zhang, S., Cao, S., Yang, Z. H., Pang, Z., & Jiang, X. (2014) · Molecular Pharmaceutics · doi:10.1021/mp500113p · Cited by 155 · see citing works
Self-citationMolavi, F., Barzegar-Jalali, M., & Hamishehkar, H. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.01.028 · Cited by 148 · see citing works
Alajangi, H. K., Kaur, M., Sharma, A., Rana, S., Thakur, S., Chatterjee, M., Singla, N., Jaiswal, P. K., Singh, G., & Barnwal, R. P. (2022) · Molecular Brain · doi:10.1186/s13041-022-00937-4 · Cited by 130 · see citing works
Immune Escape in Glioblastoma Multiforme and the Adaptation of Immunotherapies for Treatment
Pearson, J. R. D., Cuzzubbo, S., McArthur, S., Durrant, L. G., Adhikaree, J., Tinsley, C. J., Pockley, A. G., & McArdle, S. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.582106 · Cited by 118 · see citing works
Targeting receptor-ligand chemistry for drug delivery across blood-brain barrier in brain diseases
Anthony, D. P., Hegde, M., Shetty, S. S., Rafic, T., Mutalik, S., & Rao, B. S. S. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119326 · Cited by 110 · see citing works
Ruan, S., Qian, J., Shen, S., et al. (2014) · Nanoscale · doi:10.1039/c4nr02657h · Cited by 105 · see citing works
Self-citationSystemic delivery to central nervous system by engineered PLGA nanoparticles.
Cai, Q., Wang, L., Deng, G., Liu, J., Chen, Q., & Chen, Z. (2016) · PubMed Central · Cited by 97 · see citing works
Improta, G., Cesarelli, M., Montuori, P., Santillo, L. C., & Triassi, M. (2018) · Journal of Evaluation in Clinical Practice · doi:10.1111/jep.12844 · Cited by 78 · see citing works
“That is, they are expected to have both technical and managerial competences.(46,47) We recently applied LSS to reducing the number of patients affected by sentinel bacterial in surgery departments,(48) which resulted in a significant reduction in both the number of hospitalization days and the number of patients with…”
BackgroundThangudu, S., Cheng, F., & Su, C. (2020) · Polymers · doi:10.3390/polym12123055 · Cited by 65 · see citing works
“Transferrin receptor [43], Nicotinic acetylcholine receptor [44], Insulin receptor [45], Leptin receptor [45], Lipoprotein receptor [46], Neonatal Fc receptor [38], Diphtheria toxin receptor [45] Taurine transporter [37], Amino acid transporter [47], Polypeptide transporter [37], Organic anio transporter [45], ATP-bin…”
BackgroundGao, H., Zhang, Q., Yang, Y., et al. (2014) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2014.11.029 · Cited by 64 · see citing works
Self-citationNeves, V., Aires‐da‐Silva, F., Morais, M., Gano, L., Ribeiro, E., Pinto, A. R. T., Aguiar, S. I., Gaspar, D., Fernandes, C., Correia, J. D. G., et al. (2017) · ACS Chemical Biology · doi:10.1021/acschembio.7b00087 · Cited by 57 · see citing works
Madadi, A. K., & Sohn, M. (2024) · Pharmaceuticals · doi:10.3390/ph17081070 · Cited by 52 · see citing works
“…receptor-mediated, transporter-mediated, and pharmacological disruption of the BBB. Strategies include decorating delivery systems with BBB receptor ligands, coupling antibodies, peptides, or aptamers with BBB receptor ligands, and using transporter ligands coupled with micelle delivery [209].”
MethodLi, J., Long, Q., Ding, H., Wang, Y., Luo, D., Li, Z., & Zhang, W. (2024) · Advanced Science · doi:10.1002/advs.202308677 · Cited by 47 · see citing works
Recent advances in zwitterionic nanoscale drug delivery systems to overcome biological barriers
Ouyang, X., Liu, Y., Zheng, K., Pang, Z., & Peng, S. (2023) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2023.100883 · Cited by 45 · see citing works
Which drug or drug delivery system can change clinical practice for brain tumor therapy?
Siegal, T. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not016 · Cited by 45 · see citing works
Multiple functionalized carbon quantum dots for targeting glioma and tissue imaging
Gao, L., Zhao, X., Wang, J., et al. (2017) · Optical Materials · doi:10.1016/j.optmat.2017.11.044 · Cited by 39 · see citing works
Goyal, K., Konar, A., Kumar, B. S. H., & Koul, V. (2018) · Nanoscale · doi:10.1039/c8nr03828g · Cited by 38 · see citing works
Liu, Y., Ma, Y., Xu, J., Chen, Y., Xie, J., Yue, P., Zheng, Q., & Ming, Y. (2017) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2017.10.009 · Cited by 37 · see citing works
Fu, A., Zhao, Z., Gao, F., & Zhang, M. (2013) · Pharmaceutical Research · doi:10.1007/s11095-013-1068-6 · Cited by 34 · see citing works
“Targeted delivery of drugmolecules to brain is one of themost challenging research areas in pharmaceutical sciences (26,27).”
Oxime Therapy for Brain AChE Reactivation and Neuroprotection after Organophosphate Poisoning
Kuznetsova, D. A., Gaynanova, G. A., Vasilieva, E. A., Pavlov, R. V., Zueva, I. V., Babaev, V. M., Kuznetsov, D. M., Voloshina, A. D., Petrov, K. A., Zakharova, L. Y., et al. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091950 · Cited by 30 · see citing works
The removal of percutaneous Kirschner wires used in the stabilisation of fractures in children.
Symons, S., Persad, R., & Paterson, M. (2005) · PubMed · Cited by 28 · see citing works
Dynamic nanoassemblies for imaging and therapy of neurological disorders
Zhang, L., Sun, H., Zhao, J., Lee, J., Low, L. E., Gong, L., Chen, Y., Wang, N., Zhu, C., Lin, P., et al. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113832 · Cited by 27 · see citing works
Functionalized carbon nano onion as a novel drug delivery system for brain targeting
Majumder, R., Pal, T., Basumallick, A., & Mukhopadhyay, C. D. (2021) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2021.102414 · Cited by 21 · see citing works
Le Formiche Della Venezia Giulia E Della Dalmazia.
Müller, G. (1923) · INFM-OAR (INFN Catania) · doi:10.5281/zenodo.25749 · Cited by 20 · see citing works
Perspective on brain targeting drug delivery systems
Gao, H. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-814001-7.00018-4 · Cited by 19 · see citing works
Polymer Nanomaterials for Drug Delivery Across the Blood Brain Barrier
Kabanov, A. V., & Batrakova, E. V. (2016) · Springer eBooks · doi:10.1007/978-3-319-44022-4_50 · Cited by 21 · see citing works
Nanocarriers for brain specific delivery of anti-retro viral drugs: challenges and achievements
Varghese, N. M., Venkatachalam, S., & Saxena, S. K. (2017) · Journal of drug targeting · doi:10.1080/1061186x.2017.1374389 · Cited by 17 · see citing works
“Lack of tissue specificity is a major limitation and a challenging problem faced by the formulation scientist for site specific delivery of the drug particularly to the brain [102].”
BackgroundNeuropharmacology: Oxime antidotes for organophosphate pesticide and nerve agent poisoning
Zorbaz, T. (2020) · Periodicum Biologorum · doi:10.18054/pb.v121-122i1-2.10623 · Cited by 15 · see citing works
“Drugs can be absorbed from the nasal cavity by olfactory mucosa (5-10% of surface) directly to the brain via olfactory epithelium cells or nerves or they can be absorbed by the respiratory mucosa to systemic circulation and then distributed to the brain across the BBB (102).”
BackgroundKhan, S., Bano, N., Ahamad, S., Dar, N. J., Nazir, A., & Bhat, S. A. (2024) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2024.216206 · Cited by 14 · see citing works
Govender, T., Choonara, Y. E., Kumar, P., Bijukumar, D. R., du Toit, L. C., Modi, G., Naidoo, D., & Pillay, V. (2016) · Pharmaceutical Development and Technology · doi:10.1080/10837450.2016.1189937 · Cited by 11 · see citing works
Advances in Antibody-Based Therapeutics for Cerebral Ischemia
Sun, J., Yen, T., Jan, J., Mwale, P. F., Teng, R.-D., Taliyan, R., Hsieh, C.-T., & Yang, C. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics15010145 · Cited by 11 · see citing works
Nanoparticle delivery for central nervous system diseases and its clinical application
Tang, L., Zhang, R., Wang, Y., Liu, M., Hu, D., Wang, Y., & Li, Y. (2024) · Nano Research · doi:10.1007/s12274-024-6598-1 · Cited by 8 · see citing works
Kumar, V., & Gupta, U. D. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.104466 · Cited by 8 · see citing works
Photonic Nanoparticles: Emerging Theranostics in Cancer Treatment
Shahcheraghi, S. H., Shahcheraghi, S. H., Lotfi, M., Lotfi, M., Khaleghinejad, S. H., Tambuwala, Z. M., Mishra, V. K., Mishra, Y., Serrano‐Aroca, Á., Aljabali, A. A. A., et al. (2023) · Therapeutic Delivery · doi:10.4155/tde-2023-0011 · Cited by 7 · see citing works
Metal Nanoparticles in Management of Diseases of the Central Nervous System
Ingle, A. P., SHENDE, S. S., Gupta, I. R., Nagaonkar, D., Pandit, R., Paralikar, P., & Rai, M. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-813806-9.00005-6 · Cited by 9 · see citing works
Protein-Based Drug Delivery in Brain Tumor Therapy
Hwang, H. H., & Lee, D. Y. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-3258-0_13 · Cited by 6 · see citing works
Advances in Neurotherapeutic Delivery Technologies
Mr Pradeep, K. (2015) · OMICS International eBooks · doi:10.4172/978-1-63278-036-2-037 · Cited by 6 · see citing works
Inorganic Nanoparticles for Brain Targeting Scope and Limitations
Ahmed, H., Singh, S., & Alexander, A. (2024) · Springer eBooks · doi:10.1007/978-981-97-2859-6_7 · Cited by 6 · see citing works
Brain targeting with lipidic nanocarriers
Antimisiaris, S. G., Mourtas, S., & Παπαδιά, Κ. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-813667-6.00007-3 · Cited by 5 · see citing works
Potential nanocarriers for the delivery of drugs to the brain
Varghese, N. M., & Venkatachalam, S. (2020) · Elsevier eBooks · doi:10.1016/b978-0-08-102985-5.00019-x · Cited by 4 · see citing works
Current Research on Pro-drug Therapies for Parkinson's and Alzheimer's Disease
Huo, C., Wu, L., Jiang, Z., Yang, J., Wang, Z., Li, Y., & Qian, S. (2021) · Medicinal Chemistry · doi:10.2174/1573406418666211130150821 · Cited by 3 · see citing works
Brain Delivery Using Nanotechnology
Gao, H., & Jiang, X. (2015) · doi:10.1002/9781118788523.ch24 · Cited by 3 · see citing works
Self-citationLiposome-based targeted delivery of anticancer drugs for effective therapy of brain tumors
Shah, M. R., Imran, M. A., & Ullah, S. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816773-1.00003-1 · Cited by 2 · see citing works
Surface Active Ligands for Enhanced Brain Targeting of Nanoparticles
Prabakaran, A., Vashist, R., Sangave, S. D., & Alexander, A. (2024) · Springer eBooks · doi:10.1007/978-981-97-2859-6_9 · Cited by 2 · see citing works
Wang, L., Li, X., Ying, M., et al. (2023) · doi:10.1002/9781119660699.ch19 · Cited by 2 · see citing works
Natural Antibodies: Protecting Role of IgM in Glioblastoma and Brain Tumours
Semwal, S., Boukherroub, R., Savvides, S. N., & Bouckaert, J. M. J. (2021) · Current Pharmaceutical Design · doi:10.2174/1381612827666210728103524 · Cited by 1 · see citing works
“Apart from this, only a few of them are undergoing clinical trials for GBM, and none of them are close to being approved [169-171].”
BackgroundWorking Towards a Cancer Cell Selective and Brain Penetrating Anti Glioma Drug
Middleton, K. N. (2016)
Multifunctional Polymeric Nanocarriers for Targeted Brain Delivery
Zhang, Z., & Lampe, K. J. (2022) · Springer eBooks · doi:10.1007/978-3-031-11409-0_7
- Authors
- Guo, L., Ren, J., & Jiang, X.
- Affiliations
- Fudan University (CN)
- Corresponding author
- Jiang, Xinguo
- ORCID
- Ren, Jinfeng
- Venue
- Current Pharmaceutical Biotechnology
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2012-10-01
- Volume
- 13
- Issue
- 12
- Pages
- 2310-2318
- ISSN
- 1389-2010 (ISSN-L)
- OpenAlex
- W2138967764
- Cited by
- 57
- References
- 0
- Citations by year
- 2024: 6 · 2023: 4 · 2022: 4 · 2021: 6 · 2020: 7 · 2019: 2 · 2018: 7 · 2017: 5 · 2016: 5 · 2015: 2 · 2014: 5 · 2013: 3
- FWCI
- 1.61
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Pharmaceutical Biotechnology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Keywords
- blood-brain barrier, receptor-mediated transcytosis, prodrugs, P-glycoprotein inhibition, blood-brain barrier disruption, chemical delivery systems, central nervous system disorders, colloidal drug delivery
- MeSH terms
- Animals, Brain, Central Nervous System Diseases, Endocytosis, Humans, Nasal Cavity, Drug Delivery Systems, Membrane Transport Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
